MARKET

AVEO

AVEO

Aveo Pharma
NASDAQ
8.10
-0.07
-0.86%
Opening 11:43 09/29 EDT
OPEN
8.10
PREV CLOSE
8.17
HIGH
8.33
LOW
7.96
VOLUME
98.61K
TURNOVER
452.32K
52 WEEK HIGH
9.37
52 WEEK LOW
3.060
MARKET CAP
280.38M
P/E (TTM)
-7.7180
1D
5D
1M
3M
1Y
5Y
Here's What Could Help AVEO (AVEO) Maintain Its Recent Price Strength
AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zacks · 5h ago
AVEO Oncology Announces Participation at the Cantor Fitzgerald Oncology & HemOnc Conference
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that Michael Bail...
GlobeNewswire · 09/21 12:30
Fight Back Against Inflation with New Analyst Coverage
Check out this new analyst coverage screen to help investors find stocks that are gaining more attention from Wall Street analysts that could be potential winners in the fourth quarter of 2022 and beyond.
Zacks · 09/20 18:11
New Analysts Initiate Coverage: 3 Top-Ranked Stocks to Buy
Increased analyst coverage over the past few weeks may lead to solid price appreciation for stocks like Terns Pharmaceuticals (TERN), Napco Security (NSSC) and AVEO.
Zacks · 09/20 13:09
Is AVEO Pharmaceuticals (AVEO) Outperforming Other Medical Stocks This Year?
Here is how AVEO Pharmaceuticals (AVEO) and Trevi Therapeutics, Inc. (TRVI) have performed compared to their sector so far this year.
Zacks · 09/14 13:40
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Benzinga · 09/02 12:07
AVEO Oncology Announces Participation at Investor Conferences in September
BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer, today announced that members of it...
GlobeNewswire · 08/31 12:30
Nasdaq Drops 200 Points; American Woodmark Shares Spike Higher
U.S. stocks extended losses toward the end of trading, with the Nasdaq Composite dropping around 200 points on Tuesday
Benzinga · 08/30 18:32
More
About AVEO
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The Company’s commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. It also develops FOTIVDA in immuno-oncology combinations in refractory RCC and other indications and has several other investigational programs in clinical development. The Company’s pipeline of product candidates includes ficlatuzumab, AV-380, AV-203 and AV-353. Its ficlatuzumab is a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor (HGF).

Webull offers kinds of Aveo Pharmaceuticals Inc stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.